Name: Mespere LifeSciences – Integrated non-invasive haemodynamic platform
Technical specifications: Combines four sensor systems: NeurOs Cerebral Oximetry (regional cerebral saturation), VENUS 2000 CVP (central venous pressure), VO 100 (jugular oximetry), VenArt (cardiac output). Near-infrared spectroscopy (NIRS) technology with reusable sensors. Accuracy: ±1.5% cerebral saturation, ±2.16 mmHg CVP, ±2% venous oximetry.
Target patients: Critical and chronic patients: septic shock, decompensated heart failure, head trauma, post-cardiac surgery, ARDS, ECMO resuscitation, renal failure.
Clinical applications: Management of sepsis and septic shock, early detection of venous congestion in heart failure, guidance for ECMO weaning, post-traumatic neurological monitoring, optimisation of perioperative cardiac output.
Specific features: Completely non-invasive, eliminating the risk of catheter infection. Real-time monitoring with curve and trend visualisation. Multi-platform compatible (tablets, computers, third-party monitors). Home use with remote monitoring. Reusable sensors drastically reducing costs.
Patient benefits: Reduced infections, improved comfort without invasive catheters, improved prognosis through early detection of haemodynamic derailments, reduced hospital readmissions, improved quality of life.
Clinician benefits: Reliable and rapid therapeutic decisions, optimisation of vascular filling reducing complications, objective data for clinical guidance, ISO 13485 certifications and FDA/CE/Health Canada approvals guaranteeing reliability.
